NCT Number: NCT00160173
Efficacy Study Comparing 0.9 g and 1.25 g Estrogel With Placebo for Vasomotor Symptoms and Vulvar and Vaginal Atrophy
This study is intended to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause.
Looking for future studies?
Notify MeKey information
Conditions
Age range
45 year–65 year
Sex eligibility
Female
Study type
Interventional
Phase
Phase 4
Primary location
Site 112, Birmingham, Alabama, United States
About this study
The primary objective of this study was to establish the lowest effective dose of EstroGel® for the treatment of vasomotor symptoms associated with menopause by comparing the efficacy of 0.9 g and 1.25 g EstroGel® 0.03% doses with placebo. Effects on symptoms of vulvar and vaginal atrophy were assessed as secondary efficacy parameters.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Women 45-65 years
- naturally or surgically postmenopausal
- experiencing hot flushes
Exclusion criteria
- hypersensitivity to estrogen replacement therapy
- pregnancy or lactating
- abnormal PAP smear
- history/suspected cervical, uterine, adrenal, pituitary, breast or ovarian malignancy
Treatment and study plan
Placebo
OtherSponsors and collaborators
Lead sponsor
ASCEND Therapeutics
Industry
Collaborators
- Solvay Pharmaceuticals
Registry information
Official study title
Efficacy Study Comparing 0.9 g and 1.25 g EstroGel® 0.03% Doses With Placebo in the Treatment of Vasomotor Symptoms and Vulvar and Vaginal Atrophy Associated With Menopause
Important dates
- Study start
- 2004
- Primary completion
- 2005
- Study completion
- 2005
- First posted
- Sep 12, 2005
- Registry last updated
- Sep 13, 2022
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Examination of the Effects of Pelvic Floor Exercises on Vaginal and Sexual Health in Postmenopausal Women.
NCT06294197
Dyspareunia, Female Urogenital Diseases
Istanbul, Fatih, Turkey (Türkiye)
View Trial DetailsTelerehabilitation Versus Supervised Pelvic Floor Muscle Training in Urinary Incontinence
NCT07151170
Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications
Islamabad, Pakistan
View Trial DetailsCholinergic Health After Menopause (CHAMP)
NCT04129060
Aging, Alzheimer Disease
Nashville, Tennessee, United States
View Trial DetailsHigh Intensity Interval Training in Pre and Postmenopausal Women With Type II Diabetes.
NCT07258316
Diabetes Mellitus, Diabetes Mellitus, Type 2
Islamabad, Islamabad Capital Territory, Pakistan, Pakistan
View Trial Details